latest news releases from the newsroom
Heritage Oaks Bancorp
Heritage Oaks Bancorp Reports Third Quarter Results
PASO ROBLES, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Heritage Oaks Bancorp ("Heritage Oaks" or the "Company") (Nasdaq:HEOP), a bank holding company and the parent of Heritage Oaks Bank (the "Bank"), reported net income available to common shareholders of $3.4 million, or $0.10 per dilutive common share, for the third quarter of 2014 compared to net income available to common shareholders of $2.6 million, or $0.10 per dilutive common share, for the third quarter of 2013, and net income available to common shareholders of $2.9 million, or $0.09 per dilutive common share for the second quarter of 2014. For the first nine months of 2014, net income available to common shareholders was $4.6 million, or $0.14 per dilutive common share, compared with net income available to common shareholders of $8.3 million, or $0.31 per dilutive common share for the same period in 2013. The increase in net income for the third quarter of 2014 as compared to the same quarter a year earlier, was primarily due to the increased pre-tax net income resulting from the inclusion of the operating results of Mission Community Bancorp ("MISN") into the Company's operating results, which was acquired through a merger that closed on February 28, 2014 (the "MISN Transaction"). In addition, during the quarter ended September 30, 2013, the Company incurred $0.2 million in dividends and accretion on preferred stock, which was not incurred during the same period in 2014 because the Company repurchased the TARP Preferred Shares in the third quarter of 2013.
Territorial Bancorp Inc.
Territorial Bancorp Inc. Announces Third Quarter 2014 Results
HONOLULU, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Territorial Bancorp Inc. (Nasdaq:TBNK) (the "Company"), headquartered in Honolulu, Hawaii, the holding company parent of Territorial Savings Bank, announced net income of $3.5 million or $0.38 per basic and $0.37 per diluted share for the three months ended September 30, 2014, compared to $3.8 million or $0.40 per basic and $0.39 per diluted share for the three months ended September 30, 2013. The decline in net income for the third quarter of 2014 was primarily due to decreases in gains on sales of investment securities and gains on sale of loans, and an increase in noninterest expense. These were partially offset by an increase in interest income on loans and investment securities.
Harsco Corporation Declares Regular Quarterly Cash Dividend
CAMP HILL, Pa., Oct. 30, 2014 (GLOBE NEWSWIRE) -- The Board of Directors of Harsco Corporation (NYSE:HSC) has declared a regular quarterly cash dividend of $0.205 per share, or $0.82 per share on an annualized basis, payable February 17, 2015 to shareholders of record at the close of business on January 15, 2015.
Oplink Communications, Inc.
Oplink Reports First Quarter of Fiscal Year 2015 Financial Results
FREMONT, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Oplink Communications, Inc. (Nasdaq:OPLK), a leading provider of optical communication components, intelligent modules and subsystems, today reported its financial results for its quarter ended September 28, 2014, the first quarter of its 2015 fiscal year.
Zogenix Announces Conference Call and Webcast to Present Third Quarter 2014 Financial Results
SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the third quarter ended September 30, 2014, after the market closes on Thursday November 6, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.
NeoStem Announces Third Quarter 2014 Financial Results and Outlines Near Term Milestones
NEW YORK, Oct. 30, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based therapeutics designed to prevent, treat or cure disease, today announced financial results for the third quarter of 2014 and also described important expected milestones related to its clinical programs. Near term anticipated events include data release from the Phase 2 PreSERVE AMI clinical trial evaluating NBS10 in the treatment of damaged heart muscle following a heart attack and the commencement of patient enrollment in the Phase 3 Intus clinical trial, evaluating NBS20 in the treatment of malignant melanoma.